Connecting linkedin

W1siziisijiwmtqvmtavmjgvmtuvndmvmtcvntuxl2zpbguixsxbinailcj0ahvtyiisijiwmdb4nzawxhuwmdnjil1d

Biotech M&A is MIA

29/04/2014 by

W1siziisijiwmtqvmtavmjgvmtuvndmvmtcvntuxl2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0

A Pfizer (PFE) proposal to acquire Gilead Sciences (GILD) would have been audacious. Expensive? Surely, but merging the largest pharma company with the largest (and hottest) biotech company would have been game changing. Investors would have cheered such a deal.

Would have…

Instead, Pfizer is sticking with the tired, mega-pharma merger playbook. It wants to acquire AstraZeneca (AZN) in a deal that will likely cost more than $100 billion. AstraZeneca is rebuffing Pfizer’s offer for now, but in the coming weeks, we’re sure to hear much about how a union of Pfizer and AstraZeneca will yield operational synergies and cost savings, thereby delivering shareholder value.

This article has been extracted from http://www.thestreet.com, please click on this link to read the article in full http://www.thestreet.com/story/12684271/1/biotech-ma-is-mia.html

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

For more information please visit www.montash.com

Our

Latest Blogs